Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma
Yıl: 2021 Cilt: 36 Sayı: 2 Sayfa Aralığı: 206 - 214 Metin Dili: Türkçe DOI: 10.5505/tjo.2021.2660 İndeks Tarihi: 04-06-2022
Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma
Öz: Epileptic seizures are prognostic for low-grade gliomas. However, the impact of anti-epileptic drug use
(AED) on outcomes is unclear. We aimed to evaluate the impact of epileptic seizures and AED use on
tumor control and survival rates after radiotherapy (RT) in patients with World Health Organization
Grade II glioma.
METHODS
A total of 182 patients who underwent RT either early after surgery or in case of progression were retrospectively
evaluated. The primary end point was the impact of seizures on overall survival (OS), local
control (LC), and progression-free survival (PFS) rates. The secondary end point was the impact of AED
use on these rates.
RESULTS
Median follow-up was 80 months. The number of patients with epileptic seizures at the time of diagnosis
was 113 (62%). The 2-, 5-, and 10-year OS, LC, and PFS rates were significantly higher in patients
with seizures (p=0.022 and p=0.001, respectively). When patients that did and did not use AED were
compared, OS, LC, and PFS rates were similar. Besides, using AEDs in patients without seizures did not
affect the OS, LC, and PFS rates. Carbamazepine use was associated with higher OS and PFS rates with
a non-significant increase in LC. Phenytoin use yielded an increase in the PFS and LC rates in the first 2
years which turned to opposite after the 6th year.
CONCLUSION
Seizures at the time of diagnosis and using AEDs for the treatment of seizures both increase survival rates in patients
with Grade II glioma. Patients using carbamazepine had increased survival rates.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. World Health Organization histological classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97–109.
- 2. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005;366(9490):985–90.
- 3. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on doseresponse in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996;36(3):549–56.
- 4. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol 2002;20(9):2267–76.
- 5. Kahlenberg CA, Fadul CE, Roberts DW, Thadani VM, Bujarski KA, Scott RC, et al. Seizure prognosis of patients with low-grade tumors. Seizure 2012;21(7):540–5.
- 6. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with lowgrade gliomas. J Neurosurg 2008;108(2):227–35.
- 7. Danfors T, Ribom D, Berntsson SG, Smits A. Epileptic seizures and survival in early disease of grade 2 gliomas. Eur J Neurol 2009;16(7):823–31.
- 8. Yuan Y, Xiang W, Qing M, Yanhui L, Jiewen L, Yunhe M. Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review. Seizure 2014;23(10):830–5.
- 9. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical Article. J Neurosurg 2009;111(2):282–92.
- 10. Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical Article. J Neurosurg 2011;114(3):604–12.
- 11. Iuchi T, Hasegawa Y, Kawasaki K, Sakaida T. Epilepsy in patients with gliomas: incidence and control of seizures. J Clin Neurosci 2015;22(1):87–91.
- 12. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 2013;15(7):961–7.
- 13. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro Oncol 2016;18(6):779–89.
- 14. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 2012;14(2):230–41.
- 15. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54(3):551–63.
- 16. Brodie MJ, Sills GJ. Combining antiepileptic drugs-- rational polytherapy? Seizure 2011;20(5):369–75.
- 17. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S, et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012;31(44):4677–88.
- 18. Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT. Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through Redox regulation. J Mol Med (Berl) 2011;89(3):303–15.
- 19. Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol 2012;107(1):61–7.
- 20. Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p53-Mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010;12(9):917–27.
- 21. Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, et al. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 2015;121(17):2926–32.
- 22. Redjal N, Reinshagen C, Le A, Walcott BP, McDonnell E, Dietrich J, et al. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. J Neurooncol 2016;127(3):505–14.
- 23. Knudsen-Baas KM, Engeland A, Gilhus NE, Storstein AM, Owe JF. Does the choice of antiepileptic drug affect survival in glioblastoma patients? J Neurooncol 2016;129(3):461–9.
- 24. Cacho-Diaz B, San-Juan D, Salmeron K, Boyzo C, Lorenzana-Mendoza N. Choice of antiepileptic drugs affects the outcome in cancer patients with seizures. Clin Transl Oncol 2018;20(12):1571–6.
- 25. Wychowski T, Wang H, Buniak L, Henry JC, Mohile N. Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. Clin Neurol Neurosurg 2013;115(11):2365–9.
- 26. Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. Neurology 2009;72(1):8–10.
- 27. Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 2013;118(4):873–83.
- 28. Liang S, Zhang J, Zhang S, Fu X. Epilepsy in adults with supratentorial glioblastoma: incidence and influence factors and prophylaxis in 184 patients. PLoS One 2016;11(7):e0158206.
- 29. Berendsen S, Varkila M, Kroonen J, Seute T, Snijders TJ, Kauw F, et al. Prognostic relevance of epilepsy at presentation in glioblastoma patients. Neuro Oncol 2016;18(5):700–6.
| APA | YÜCE SARI S, YAZICI G, CENGİZ M, Zorlu F, ÇAĞLAR A (2021). Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. , 206 - 214. 10.5505/tjo.2021.2660 |
| Chicago | YÜCE SARI Sezin,YAZICI Gözde,CENGİZ Mustafa,Zorlu Faruk,ÇAĞLAR Ahmetcan Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. (2021): 206 - 214. 10.5505/tjo.2021.2660 |
| MLA | YÜCE SARI Sezin,YAZICI Gözde,CENGİZ Mustafa,Zorlu Faruk,ÇAĞLAR Ahmetcan Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. , 2021, ss.206 - 214. 10.5505/tjo.2021.2660 |
| AMA | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. . 2021; 206 - 214. 10.5505/tjo.2021.2660 |
| Vancouver | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. . 2021; 206 - 214. 10.5505/tjo.2021.2660 |
| IEEE | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A "Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma." , ss.206 - 214, 2021. 10.5505/tjo.2021.2660 |
| ISNAD | YÜCE SARI, Sezin vd. "Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma". (2021), 206-214. https://doi.org/10.5505/tjo.2021.2660 |
| APA | YÜCE SARI S, YAZICI G, CENGİZ M, Zorlu F, ÇAĞLAR A (2021). Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. Türk Onkoloji Dergisi, 36(2), 206 - 214. 10.5505/tjo.2021.2660 |
| Chicago | YÜCE SARI Sezin,YAZICI Gözde,CENGİZ Mustafa,Zorlu Faruk,ÇAĞLAR Ahmetcan Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. Türk Onkoloji Dergisi 36, no.2 (2021): 206 - 214. 10.5505/tjo.2021.2660 |
| MLA | YÜCE SARI Sezin,YAZICI Gözde,CENGİZ Mustafa,Zorlu Faruk,ÇAĞLAR Ahmetcan Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. Türk Onkoloji Dergisi, vol.36, no.2, 2021, ss.206 - 214. 10.5505/tjo.2021.2660 |
| AMA | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. Türk Onkoloji Dergisi. 2021; 36(2): 206 - 214. 10.5505/tjo.2021.2660 |
| Vancouver | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma. Türk Onkoloji Dergisi. 2021; 36(2): 206 - 214. 10.5505/tjo.2021.2660 |
| IEEE | YÜCE SARI S,YAZICI G,CENGİZ M,Zorlu F,ÇAĞLAR A "Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma." Türk Onkoloji Dergisi, 36, ss.206 - 214, 2021. 10.5505/tjo.2021.2660 |
| ISNAD | YÜCE SARI, Sezin vd. "Impact of Seizures and Anti-epileptic Drug Use on Survival in Patients with World Health Organization Grade II Glioma". Türk Onkoloji Dergisi 36/2 (2021), 206-214. https://doi.org/10.5505/tjo.2021.2660 |
